The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts
Peer-Reviewed Publication
Updates every hour. Last Updated: 14-Dec-2025 13:11 ET (14-Dec-2025 18:11 GMT/UTC)
This review discusses the evolution, challenges, and innovations of antibody-drug conjugates (ADCs) in cancer treatment. It focuses on the importance of precise target selection and engineering to improve efficacy while minimizing off-target toxicities. Recent advances such as pH-dependent antibodies, dual-epitope targeting, and AI-guided profiling are highlighted as promising strategies to enhance safety and therapeutic impact.
Researchers found a new adverse outcome pathway (AOP) for locomotor impairment initiated by TDCPP binding to integrin αvβ3 and established a quantitative response-response relationship linking integrin αvβ3 and locomotor impairment. These results further deepen the understanding of organophosphate esters -induced neurodevelopmental toxicity and thus provide a basis for the development of new AOPs.
This study reports two cryo-EM structures of the Nipah virus (NiV) polymerase L-P complex in its full-length and truncated forms. These structures elucidate the RNA-dependent RNA polymerase (RdRp) and polyribonucleotidyl transferase (PRNTase) domains of the L protein, as well as the tetrameric P protein bundle bound to the L-RdRp. This work establishes a foundational framework for understanding the NiV polymerase mechanism and provides critical insights for the rational design of antiviral therapeutics targeting the polymerase complex
This perspective highlights the critical role of region-specific gut microbial distribution across intestinal segments (e.g., duodenum, colon) in regulating host metabolism and immunity, challenging traditional fecal-centric approaches. It emphasizes bile acid metabolism and small intestinal bacterial overgrowth (SIBO) in metabolic diseases like diabetes, proposing targeted interventions such as duodenal mucosal resection and probiotics to restore microbial niches. The study underscores AI-driven strategies for precision therapies addressing spatial microbial dynamics, offering novel pathways for disease therapeutics
A Japanese superconducting quantum computer, designed and built with homegrown components and software, went live on July 28th at The University of Osaka’s Center for Quantum Information and Quantum Biology (QIQB). This achievement signifies Japan's technological prowess in quantum computing, demonstrating the nation's capacity to design, manufacture, and integrate a complete quantum system. Visitors to Expo 2025, Osaka, Kansai, Japan will have the opportunity to interact with this cutting-edge technology through a dedicated exhibit.